A primer-probe sequence combination, kit, method, and application for simultaneous detection of multiple cis-trans mutation combinations in EGFR.
By designing a single-tube real-time PCR method that combines a specific repression probe with a Taqman probe, the problem of detecting multiple cis-trans mutation combinations in EGFR has been solved. This method enables rapid and low-cost detection, reduces the false negative rate, and meets the needs of early tracking and treatment of drug-resistant gene mutations.
Patent Information
- Application Number
- CN202211117325.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-14
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2042-09-14
AI Technical Summary
Existing technologies are insufficient for efficiently and cost-effectively detecting multiple cis-trans mutation combinations in EGFR, especially the low proportion of amino acid alterations at EGFR C797 and G796 sites, leading to missed detection of drug resistance gene mutations and affecting treatment efficacy.
We designed specific repression probes to bind with Taqman probes, and used a competitive relationship to detect wild-type and mutant EGFR sites at 796-797. We used single-tube quantitative PCR to simultaneously detect multiple base mutations, avoiding cumbersome operations.
It enables rapid and low-cost detection of multiple cis-trans mutations in EGFR, reduces the false negative rate, meets the needs of early tracking and treatment of drug-resistant gene mutations, and replaces expensive next-generation sequencing technology.
Smart Images

Figure CN116622844B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, and specifically relates to a primer-probe sequence combination, kit, method and application, particularly to a primer-probe sequence combination, kit, method and application for simultaneously detecting multiple cis-trans mutation combinations of EGFR. Background Technology
[0002] For EGFR mutation-targeted therapies, first- and second-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib and gefitinib, are currently the most widely used and effective drugs. However, most patients develop drug resistance within 1-2 years after using first- and second-generation EGFR-TKIs, leading to tumor recurrence and growth. This resistance is caused by new drug-resistant gene mutations in the EGFR target (such as EGFR T790M). The original EGFR drug-sensitive gene mutation may disappear or coexist with the new drug-resistant gene mutation. Third-generation anti-EGFR-TKIs (such as osimertinib) have been approved for use in China to target the new EGFR T790M mutation. However, new gene mutations and drug resistance may also occur after 1-2 years of osimertinib use. Currently, no fourth-generation targeted drugs have been successfully developed domestically or internationally. Studies on EGFR-TKI resistance genes have shown that the main drug resistance gene resulting from the use of first- and second-generation EGFR-TKIs such as erlotinib and gefitinib is EGFR T790M (58%). Resistance gene mutations resulting from the use of the third-generation EGFR-TKI osimertinib include EGFR C797 mutation, disappearance of the primary EGFR mutation, EGFR gene amplification, MET amplification, HER2 amplification, KRAS mutation, PIK3CA mutation, FGFR1 gene amplification, and multiple gene mutations. Histological changes and other factors are of unknown cause. Figure 1 Of particular note are the two different types of the relatively common EGFR C797 mutation: cis and trans. A cis mutation occurs at the 797th position of the primary T790M mutation, meaning both mutations occur on the same gene template. A trans mutation occurs when the new C797 mutation does not occur on the same gene template as the primary T790M mutation; that is, both the T790M mutation and the newly occurring C797 mutation are present, but on different templates. Figure 2For cis mutations, there are currently no targeted drugs available; chemotherapy is the only treatment option. For trans mutations, combination therapy with first- and second-generation EGFR-TKIs and third-generation EGFR-TKIs can be used. Therefore, cis or trans mutation testing is necessary after the presence of an EGFR C797 mutation. In addition to the C797S mutation, C797G, G796S, and G796R mutations can also occur at the EGFR C797 site. Amino acid changes at positions 797 and 796 can be caused by different nucleotide base changes, such as C797S (G>C), C797S (T>A), C797G (T>G), G796S (G>A), and G796R (G>C). Currently, PCR testing can only detect the C797S mutation and its cis and trans mutations, neglecting the detection of other mutations that occur at lower rates. Because corresponding probes need to be designed for each different mutation to comprehensively detect these individual base changes and their complex combinations, PCR testing would be extremely complex.
[0003] However, the total percentage of these lower-than-average mutations is over 15%, and these mutations can be cis or trans. The neglect of testing for these mutations leads to undetected drug-resistant gene mutations in these patients, delaying treatment. For cis mutations at positions 797 and 796, regardless of the specific base mutation or the amino acid produced, there are currently no specific targeted drugs. Therefore, it is only necessary to detect whether the mutation has occurred, not to identify the specific base or amino acid mutation. Trans mutations can still be treated with combination therapy using first-, second-, and third-generation EGFR-TKIs.
[0004] Currently, methods for detecting EGFR 790 cis and trans are next-generation sequencing (NGS), digital PCR, and quantitative real-time PCR. NGS is the most intuitive method, as the sequence results clearly show the base positions of EGFR 790 and 796 / 797 on the same template, allowing for the estimation of cis or trans. Digital PCR involves designing specific probes for all corresponding mutations of T790M and 796 / 797. T790M uses one fluorescent label, while all 796 / 797 mutation probes use a different fluorescent label. If only one fluorescent label is present in the same "microreactor," it is trans; otherwise, two fluorescent labels indicate cis. [1] Quantitative real-time PCR (qPCR) mainly consists of ARMS-PCR with specific amplification primers and WTB-PCR with wild-type amplification repression. Different combinations of ARMS primers or repression probes are used to distinguish which type of the target site belongs to, and thus determine whether the detection result is cis or trans.
[0005] Disadvantages of existing technology:
[0006] 1. The detection method based on NGS technology platform has disadvantages such as long time consumption, high cost and high requirements for personnel operation skills, which are not suitable for repeated use in follow-up patients and early detection of drug resistance genes.
[0007] 2. Digital PCR requires the design of specific probes for all variants. Mixing too many probes will cause non-specific amplification, high noise, and affect the interpretation of results.
[0008] 3. Currently, the method used for detecting EGFR cis-trans PCR is the dual-repression probe method. [2-3] By designing a blocking probe to block wild types 790 and 797, the cis-trans type can be determined based on the detection results of different blocking probe combinations. This requires multiple tube operations and a control group without blocking probes, making the operation cumbersome.
[0009] Citing patent literature
[0010] [1] Huang Linting, Cao Qiansheng, Yu Ying, et al. Probe set, kit, reaction system and system for detecting T790M and C797S cis-trans mutation types: China, CN201811638547;
[0011] [2] Chu Tianqing, Chen Xi, Ding Li, et al., A method for detecting EGFR T790M and C797S cis mutations: China, CN201910315506.4;
[0012] [3] Tang Dongjiang, Zhao Jichang, Huang Yajing, Method and probe for detecting cis-trans mutant configurations of EGFR-T790M and EGFR-C797S: China, CN202010726064.5. Summary of the Invention
[0013] The purpose of this invention is to provide a primer and probe sequence combination, kit, method, and application for simultaneously detecting multiple cis-trans mutation combinations in EGFR. This invention designs a specific repression probe and uses Taqman probe detection to determine whether the mutation is linked, and solves the cumbersome operation of conventional dual repression probe methods. It can detect multiple EGFR base synonymous mutations and cis or trans types in a single test.
[0014] Therefore, the technical solution of the present invention is as follows:
[0015] In a first aspect, the present invention provides a primer-probe sequence combination for simultaneously detecting multiple cis-trans mutation combinations of EGFR, characterized in that it includes sequences SEQ ID NO:1-SEQ ID NO:5;
[0016] Wherein, SEQ ID NO:1 and SEQ ID NO:2 are amplification primer pairs, SEQ ID NO:1 is the upstream primer for amplification, and SEQ ID NO:2 is the downstream primer for amplification; the amplification primers can specifically amplify the fragment containing EGFR 790-797, and the downstream primer in the primers has at least 3 overlapping sequences with the 796-797 wild-type specific blocker;
[0017] SEQ ID NO:3 is the 790 mutant probe, and SEQ ID NO:4 is the 790 wild-type probe;
[0018] SEQ ID NO:5 is a 796-797 specific blocking blocker.
[0019] The specific sequence composition is shown in Table 1.
[0020] Table 1 SEQ ID NO:1-SEQ ID NO:5 sequences
[0021]
[0022] Preferably, the 790 mutant probe is a probe that specifically binds to the EGFR-T790M mutant, wherein the 5' end is labeled with FAM fluorescence modification and the 3' end is labeled with MGB quenching modification; that is, FAM-CAGCTCATCATGCAGC-MGB;
[0023] The 790 wild-type probe is a probe that specifically binds to EGFR-790 wild-type, wherein the 5' end is labeled with HEX fluorescence modification and the 3' end is labeled with BHQ1 quenching modification; that is, HEX-CAGCTCAT+CAC+GCAGC-BHQ1, and "+" indicates LNA modification.
[0024] Preferably, LNA modification is added to the bases at positions 796-797 where the specific repressor Blocker is prone to mutation; C3 spacer modification is added to the 3' end of the sequence; all bases in SEQ ID NO:5 are thiolated; specifically... CAGGA+G+GC+A+GC+C+G-C3Spacer, "+" indicates LNA modification, and underscore indicates thio modification. The 796-797 specific repressor blocker (hereinafter referred to as "Blocker") is a sequence that specifically binds to the wild-type EGFR 796-797. When it is a perfect match, its annealing temperature is at least 12-15℃ higher than the primer annealing temperature, which is conducive to the Blocker preferentially binding to the wild-type template. To improve recognition specificity, LNA modification is added to the bases at the positions where mutations are likely to occur in 796 and 797. To prevent self-amplification and the generation of non-specific signals, C3 spacer modification is added to the 3' end of the sequence. In addition, to enhance the sequence's resistance to exonuclease digestion, all bases are thiolated. The Blocker has the ability to bind strongly to the wild-type EGFR 796-797 sequence, and when mutations of C797S(G>C), C797S(T>A), C797G(T>G), G796S(G>A), and G796R(G>C) are present, the Blocker does not bind or its binding ability is greatly reduced.
[0025] This invention uses an EGFR 796-797 wild-type specific blocker and downstream amplification primers that compete with the blocker with at least three overlaps to inhibit the amplification of wild-type 796-797 samples. Specifically, when the detection template is 796-797 wild-type, the blocker preferentially binds to it. In this case, the 3' end of the downstream primer is blocked by the blocker, preventing normal amplification. No fluorescence signal is observed regardless of the state of the 790 probe. However, when the detection template contains a 796-797 mutant template, the blocker cannot bind, allowing the downstream primer to bind normally, amplifying the template. The fluorescence signal of the 790 probe indicates the genotype of the 790 probe. Figure 3 ).
[0026] Secondly, the present invention provides a kit for simultaneously detecting multiple cis-trans mutations in EGFR, wherein the kit includes at least the primer-probe sequence combination described in the first aspect.
[0027] Preferably, the kit further includes a PCR reaction solution; the PCR reaction solution includes at least nuclease-free water, dNTPs, magnesium ions, buffer, and Taq enzyme.
[0028] Preferably, the final concentration of each amplification primer is 100-400 nM, for example, it can be 100 nM, 120 nM, 140 nM, 160 nM, 180 nM, 200 nM, 220 nM, 240 nM, 260 nM, 280 nM, 300 nM, 320 nM, 340 nM, 360 nM, 380 nM, 400 nM and all values within the range mentioned above. Due to space limitations, these will not be elaborated further.
[0029] The final concentration of each probe is 50-200 nM, for example, it can be 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 110 nM, 120 nM, 130 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM and all values within the range mentioned above. Due to space limitations, these will not be elaborated further.
[0030] The final concentration of the specific inhibitory blocker 796-797 is 500-2000 nM, for example, it can be 500 nM, 600 nM, 700 nM, 800 nM, 900 nM, 1000 nM, 1100 nM, 1200 nM, 1300 nM, 1400 nM, 1500 nM, 1600 nM, 1700 nM, 1800 nM, 1900 nM, 2000 nM and all values within the range mentioned above. Due to space limitations, it will not be elaborated further.
[0031] Thirdly, the present invention provides the application of the primer-probe combination as described in the first aspect in the simultaneous detection of multiple cis-trans mutation combinations of EGFR.
[0032] Fourthly, the present invention provides the use of the primer-probe combination as described in the first aspect in the preparation of reagents or kits for the simultaneous detection of multiple cis-trans mutations in EGFR.
[0033] Fifthly, the present invention provides a method for simultaneously detecting multiple cis-trans mutations in EGFR, characterized by comprising the following steps:
[0034] 1) Extract DNA from the sample to be tested;
[0035] 2) Using the DNA from step 1) as a template, perform a real-time PCR amplification reaction using the primer and probe combination described in the first aspect to obtain the amplification curve and Ct value;
[0036] 3) Judge the results based on the amplification curve and Ct value.
[0037] Compared with existing technologies, the novel designs of amplification primers, 790 mutant and wild-type specific probes, and 796-797 wild-type specific repression probes provided by this invention enable the detection of EGFR C797 or EGFR G796 mutations and their cis and trans types caused by the aforementioned multiple base mutations using only a single PCR detection tube. This technology can avoid missed detections of this 15% rate of EGFR mutations. This invention only reports whether EGFR C797 or EGFR G796 drug resistance gene mutations have occurred, and reports whether the mutation is cis or trans, without reporting which base or amino acid mutation occurs in 796-797, fully meeting the needs of subsequent treatment. Due to the high sensitivity, speed, and low cost of the PCR detection of this invention, it can replace expensive and time-consuming second-generation sequencing for follow-up of third-generation EGFR-TKI osimertinib treatment, tracking the emergence of drug resistance gene mutations during treatment, and achieving the goal of early detection and timely treatment. Attached Figure Description
[0038] Figure 1 A schematic diagram illustrating the resistance mechanisms of first-line and second-line osimertinib.
[0039] Figure 2 A schematic diagram of cis and trans mutations in exon 20 of EGFR;
[0040] Figure 3 This is a schematic diagram illustrating the working principle of the present invention;
[0041] Figure 4 The results of specific identification and detection of the C797S(G>C) mutation are shown in Figures 1-5.
[0042] Figure 5 The results of specific identification and detection of the C797S(T>A) mutation are shown in Figures 6-10.
[0043] Figure 6 The results of specific identification and detection of the C797G(T>G) mutation are shown in Figure 11-15.
[0044] Figure 7 The results of specific identification and detection of the G796S (G>A) mutation are shown in Figures 16-20.
[0045] Figure 8 The results of specific identification and detection of the G796R (G>C) mutation are shown in Figures 21-25.
[0046] Figure 9 The results are shown in Figures 26 and 27.
[0047] Figure 10 The results are shown in Figures 28 and 29.
[0048] Figure 11 The results are shown in Figures 30 and 31.
[0049] Figure 12 This is a result diagram of Example 32. Detailed Implementation
[0050] Embodiments of the present invention are described in detail below, examples of which are illustrated in the accompanying drawings, wherein the same or similar reference numerals denote the same or similar elements or elements having the same or similar functions throughout. The embodiments described below with reference to the accompanying drawings are exemplary and intended to explain the present invention, and should not be construed as limiting the present invention.
[0051] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. In addition, those skilled in the art can combine and integrate the different embodiments or examples described in this specification.
[0052] Experimental materials and equipment
[0053] The primers, probes, blockers, plasmids, and magnesium ions used in the embodiments of this invention were all provided by Sangon Biotech (Shanghai) Co., Ltd.
[0054] The qPCR-related reagents and consumables (10×PCR Buffer, dNTPs, and Taq enzyme) were provided by Nanjing Novizan Biotechnology Co., Ltd.
[0055] The digital PCR instrument and related reagents and consumables (2×SuperMix, droplet generating oil, droplet generating chip, droplet detection oil and droplet detection chip) were provided by Xinyi Manufacturing Technology (Beijing) Co., Ltd.
[0056] Examples 1-31
[0057] Examples 1-31 involve diluting the DNA of plasmids 1-12, which carry different mutation information, to 1500 copies / μL, and then mixing them according to the proportions described in Table 3. The plasmid information and specific example information are shown in Tables 2 and 3.
[0058] Table 2 Plasmid Information
[0059] name mutation information Remark plasmid 1 790 wild type +796-797 wild type Wild-type plasmid plasmid 2 T790M+C797S(G>C) C797S(G>C) cis mutant plasmid plasmid 3 T790M+C797S(T>A) C797S(T>A) cis mutant plasmid plasmid 4 T790M+C797G (T>G) C797G(T>G) cis-mutant plasmid plasmid 5 T790M+G796S(G>A) G796S(G>A) cis mutant plasmid plasmid 6 T790M+G796R(G>C) G796S(G>C) cis mutant plasmid plasmid 7 T790M+796-797 Wild Type T790M mutant plasmid plasmid 8 C797S(G>C) C797S(G>C) cis mutant plasmid plasmid 9 C797S(T>A) C797S(T>A) cis mutant plasmid plasmid 10 C797G(T>G) C797G(T>G) cis-mutant plasmid plasmid 11 G796S(G>A) G796S(G>A) cis mutant plasmid plasmid 12 G796R(G>C) G796S(G>C) cis mutant plasmid
[0060] Table 3 Composition information of Examples 1-30
[0061]
[0062]
[0063]
[0064] The qPCR systems for Examples 1-31 were prepared according to Table 4, with the DNA template being the same as that in Examples 1-31. PCR amplification was performed according to the procedure described in Table 5.
[0065] Table 4. Composition and proportions of the qPCR system
[0066] name volume Final concentration 10×PCR Buffer 2.5 1× dNTPs 0.5 200μM <![CDATA[Mg 2+ ]]> 0.5 0.5mM Taq 0.1 0.02 U / μL EGFR-790-797-F 0.5 200nM EGFR-790-797-R 0.5 200nM EGFR-790Mt-P 0.25 100nM EGFR-790Wt-P 0.25 100nM EGFR-796-797-B 0.25 1000nM Nuclease-free water 14.65 - DNA template 5 300 copies / μL Total volume 25 -
[0067] Table 5 PCR amplification program
[0068]
[0069] Results Analysis
[0070] 1. Specific identification and detection of C797S(G>C) mutation (involving plasmid 1, plasmid 2, plasmid 8, Examples 1-5 and Example 26)
[0071] The specific identification and detection results of the C797S(G>C) mutation are as follows: Figure 4 and Figure 9 As shown in A, by Figure 4 The HEX fluorescence channel results from Examples 1-5 in B show that when C797 is not mutated (plasmid 1, Example 5), i.e., 796-797 is wild-type, the Blocker can effectively bind to it and inhibit primer amplification and wild-type probe hydrolysis. Therefore, there is no obvious amplification phenomenon in the HEX fluorescence channel, which is consistent with the expected results (no fluorescence signal).
[0072] Similarly, from Figure 4 The FAM fluorescence channel results from Examples 1-5 in Part A show that when the C797S (G>C) cis mutation is present (the proportion of plasmid 2 gradually decreases in Examples 1-4), the blocker cannot bind, the primers amplify normally, and the mutant probe that binds to T790M is normally hydrolyzed. Therefore, the FAM fluorescence channel shows a significant amplification phenomenon, and the Ct value increases with the decrease in the proportion of plasmid 2, showing a good linear relationship (e.g., Figure 4 As shown in C), the results were consistent with expectations, with a minimum detection limit of 1‰ (Example 4).
[0073] Conversely, by Figure 9 As shown in Example 26 of A, when the sample is trans-mutant, the HEX fluorescence channel shows obvious amplification, which is consistent with the expected result, and the lowest detection limit is 1‰.
[0074] 2. Specific identification and detection of C797S(T>A) mutation (involving plasmids 1, 3, and 9, Examples 6-10 and Example 27)
[0075] The specific identification and detection results of the C797S(T>A) mutation are as follows: Figure 5 and Figure 9 As shown in B, by Figure 5 The HEX fluorescence channel results from Examples 6-10 in B show that when C797 is not mutated (plasmid 1, Example 10), i.e., 796-797 is wild-type, the Blocker can effectively bind to it and inhibit primer amplification and wild-type probe hydrolysis. Therefore, there is no obvious amplification phenomenon in the HEX fluorescence channel, which is consistent with the expected results.
[0076] Similarly, from Figure 5 The FAM fluorescence channel results from Examples 6-10 in Part A show that when the C797S(T>A) cis-mutant is present (the proportion of plasmid 3 gradually decreases in Examples 6-9), the blocker cannot bind, the primers amplify normally, and the mutant probe bound to T790M is normally hydrolyzed. Therefore, the FAM fluorescence channel shows a significant amplification phenomenon, and the Ct value increases with the decrease in the proportion of plasmid 3, exhibiting a good linear relationship (e.g., ...). Figure 5 As shown in C), the results were consistent with expectations, with a minimum detection limit of 1‰ (Example 9).
[0077] Conversely, by Figure 9 As shown in Example 27 of B, when the sample is trans-mutant, the HEX fluorescence channel shows obvious amplification, which is consistent with the expected result, and the lowest detection limit is 1‰.
[0078] 3. Specific identification and detection of C797G (T>G) mutation (involving plasmid 1, plasmid 4, plasmid 10, Examples 11-15 and Example 28)
[0079] The specific identification and detection results of the C797G(T>G) mutation are as follows: Figure 6 and Figure 10 As shown in A, by Figure 6 The HEX fluorescence channel results from Examples 11-15 in B show that when C797 is not mutated (plasmid 1, Example 15), i.e., 796-797 is wild-type, the Blocker can effectively bind to it and inhibit primer amplification and wild-type probe hydrolysis. Therefore, there is no obvious amplification phenomenon in the HEX fluorescence channel, which is consistent with the expected results.
[0080] Similarly, from Figure 6 The results of the FAM fluorescence channel in Examples 11-15 of A show that when the C797G (T>G) cis mutation is present (the proportion of plasmid 4 gradually decreases in Examples 11-14), the Blocker cannot bind, the primers amplify normally, and the mutant probe that binds to T790M is normally hydrolyzed. Therefore, the FAM fluorescence channel shows obvious amplification, and the Ct value increases with the decrease of the proportion of plasmid 4, showing a good linear relationship (as shown in Figure 6C), which is consistent with the expected results. The lowest detection limit is 1‰.
[0081] Conversely, by Figure 10 As shown in Example 28 of A, when the sample is trans-mutant, the HEX fluorescence channel shows obvious amplification, which is consistent with the expected result, and the lowest detection limit is 1%.
[0082] 4. Specific identification and detection of the G796S (G>A) mutation (involving plasmid 1, plasmid 5, plasmid 11, Examples 16-20 and Example 29)
[0083] The specific identification and detection results of the G796S(G>A) mutation are as follows: Figure 7 and Figure 10 As shown in B, by Figure 7 The HEX fluorescence channel results from Examples 16-20 in B show that when G796 is not mutated (plasmid 1, Example 20), i.e., 796-797 are wild-type, the Blocker can effectively bind to it and inhibit primer amplification and wild-type probe hydrolysis. Therefore, there is no obvious amplification phenomenon in the HEX fluorescence channel, which is consistent with the expected results.
[0084] Similarly, from Figure 7 The FAM fluorescence channel results from Examples 16-20 in Part A show that when the G796S (G>A) cis-mutant is present (the proportion of plasmid 5 gradually decreases in Examples 16-19), the Blocker cannot bind, the primers amplify normally, and the mutant probe bound to T790M is normally hydrolyzed. Therefore, the FAM fluorescence channel shows a significant amplification phenomenon, and the Ct value increases with the decrease in the proportion of plasmid 5, exhibiting a good linear relationship (e.g., ...). Figure 7 As shown in C), the results are consistent with expectations, with a minimum detection limit of 1%.
[0085] Conversely, by Figure 10 As shown in Example 29 of B, when the sample is trans-mutant, the HEX fluorescence channel shows significant amplification, consistent with the expected results, with a minimum detection limit of 1%.
[0086] 5. Specific identification and detection of the G796R (G>C) mutation (involving plasmid 1, plasmid 6, plasmid 12, Examples 21-25 and Example 30)
[0087] The specific identification and detection results of the G796R (G>C) mutation are as follows: Figure 8 and Figure 11 As shown in A, by Figure 8 The HEX fluorescence channel results from Examples 21-25 in B show that when G796 is not mutated (plasmid 1, Example 25), i.e., 796-797 are wild-type, the Blocker can effectively bind to it and inhibit primer amplification and wild-type probe hydrolysis. Therefore, there is no obvious amplification phenomenon in the HEX fluorescence channel, which is consistent with the expected results.
[0088] Similarly, from Figure 8 The FAM fluorescence channel results from Examples 21-25 in Part A show that when the G796R (G>C) cis-mutant is present (the proportion of plasmid 6 gradually decreases in Examples 21-24), the blocker cannot bind, the primers amplify normally, and the mutant probe that binds to T790M is normally hydrolyzed. Therefore, the FAM fluorescence channel shows a significant amplification phenomenon, and the Ct value increases with the decrease in the proportion of plasmid 6, showing a good linear relationship (e.g., ...). Figure 8 As shown in C), the results are consistent with expectations, with a minimum detection limit of 1%.
[0089] Conversely, by Figure 11 As shown in Example 30 of A, when the sample is trans-mutant, the HEX fluorescence channel shows obvious amplification, which is consistent with the expected result, and the lower limit of detection is 1%.
[0090] 6. Blocker's blocking effect on wild-type plasmids 796-797 (involving plasmids 1 and 7, Examples 5, 10, 15, 20, 25 and 31)
[0091] Depend on Figure 4 B, 5B, 6B, 7B, 8B, and 11B show that when 796-797 is wild-type, the Blocker can effectively bind to it and inhibit primer amplification and wild-type or wild-type probe hydrolysis. Therefore, there is no obvious amplification phenomenon in the corresponding fluorescent channel, which is consistent with the expected results.
[0092] Example 32
[0093] This embodiment is used to test the effectiveness of the primer, probe, and blocker combination of the present invention on a digital PCR platform. Samples 1-6 of this embodiment were prepared using the plasmids in Table 2 according to Table 6. Subsequently, the digital PCR reaction system was prepared according to Table 7, wherein the DNA template was Samples 1-6 as described in Table 6 of Example 32; PCR amplification was performed according to the procedure described in Table 8.
[0094] Table 6 Information for Samples 1-6
[0095] name mutation information Remark Sample 1 10% plasmid 2 + 90% plasmid 1 10% C797S (G>C) cis-mutation Sample 2 2% plasmid 2 + 98% plasmid 1 2% C797S (G>C) cis-mutation Sample 3 0.4% plasmid 2 + 99.6% plasmid 1 0.4% C797S (G>C) cis-mutation Sample 4 0.08% plasmid 2 + 99.92% plasmid 1 0.08% C797S (G>C) cis-mutation Sample 5 0.016% plasmid 2 + 99.984% plasmid 1 0.0016% C797S (G>C) cis-mutation Sample 6 water negative control
[0096] Table 7 Digital PCR System
[0097] name volume Final concentration 2×Super Mix 12.5 1× EGFR-790-797-F 0.6 200nM EGFR-790-797-R 0.6 200nM EGFR-790Mt-P 0.3 100nM EGFR-790Wt-P 0.3 100nM EGFR-796-797-B 0.3 1000nM Nuclease-free water 2.9 - DNA template 10 500 copies / μL Total volume 30 -
[0098] Table 8 PCR Amplification Procedure
[0099]
[0100]
[0101] The steps for performing multiple cis-trans assays using digital PCR are as follows:
[0102] 1) Prepare the digital PCR reaction system according to Table 7; then add 30 μL of the above system to the "water" well of the droplet generation chip, and then add 180 μL of droplet generation oil to the "oil" well, and seal it tightly with the matching rubber cap; place the droplet generation chip in the droplet generation device to generate droplets, and place the generated droplets in the PCR eight-tube, and seal it tightly with the matching rubber cap; place the PCR eight-tube in a regular PCR instrument and perform PCR amplification according to the program in Table 8;
[0103] 2) After amplification, fix the PCR eight-tube tube to the droplet detection chip, add 430μL and 500μL of droplet detection oil to the large and small oil wells in the droplet detection chip respectively, seal tightly with the matching rubber cap, and place in the droplet detection device for droplet detection.
[0104] Results Analysis
[0105] Test Results Table 9 and Figure 12 As shown, by Figure 12 The results show that the Blocker has a good blocking effect, and no positive droplets were detected in the HEX channel. Figure 12 A shows that the copy number in the FAM channel gradually decreases as the proportion of plasmid 2 decreases, exhibiting good linearity with the actual copy number (e.g., Figure 12 As shown in C), the lowest detection limit is 0.016% (1.6 per ten thousand).
[0106] Table 9. Test Results of Example 32
[0107] Sample number Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Theoretical copy number 1500 300 60 12 2.4 0 Copy number (FAM) 1684.5 281.5 54.6 10 2.4 0 Copy number (HEX) 0 0 0 0 0 0 Total number of droplets 53270 49199 51470 56383 53970 53150 Positive droplet count (FAM) 1356 206 42 9 2 0 Positive droplet count (HEX) 0 0 0 0 0 0 negative droplet count 51914 48993 51428 56374 53968 53150
[0108] In summary, this invention provides a primer, probe, and blocker combination for detecting multiple EGFR drug resistance gene base synonymous mutations and cis-trans mutations in a single tube using qPCR or digital PCR. By designing a combination of a universal wild-type repression probe for EGFR 796-797 and a genotyping probe for 790, it can detect 790 and 796-797 mutations, and simultaneously determine the positional relationship of the two mutations on the DNA strand. This greatly reduces the cumbersome operation and potential errors of multi-tube testing, while also reducing testing costs and the amount of clinical samples required. Furthermore, using the primer, probe, and blocker combination of this invention, a digital PCR platform that generates a large number of droplets can easily break through the detection limit of 0.02%, providing a low-cost alternative to NGS for real-time monitoring of minimal residual disease (MRD).
[0109] It should be noted and understood that various modifications and improvements can be made to the invention described in the detailed description above without departing from the spirit and scope of the invention as claimed in the appended claims. Therefore, the scope of the claimed technical solutions is not limited to any specific exemplary teachings given.
[0110] The applicant declares that the above description, in conjunction with specific preferred embodiments, provides a further detailed explanation of the present invention and should not be construed as limiting the specific implementation of the invention to these descriptions. For those skilled in the art, various simple deductions or substitutions can be made without departing from the inventive concept, and all such modifications and substitutions should be considered within the scope of protection of the present invention.
Claims
1. A primer-probe sequence combination for simultaneously detecting multiple cis-trans mutation combinations in EGFR, characterized in that, Includes sequences SEQ ID NO:1-SEQ ID NO:5; wherein SEQ ID NO:1 and SEQ ID NO:2 are amplification primer pairs, SEQ ID NO:1 is the upstream amplification primer, and SEQ ID NO:2 is the downstream amplification primer; SEQ ID NO:3 is the 790 mutant probe, and SEQ ID NO:4 is the 790 wild-type probe; SEQ ID NO:5 is a 796-797 specific blocking blocker; The 790 mutant probe is a probe that specifically binds to the EGFR-T790M mutant, wherein the 5' end is labeled with FAM fluorescence modification and the 3' end is labeled with MGB quenching modification; The 790 wild-type probe is a probe that specifically binds to EGFR-790 wild-type, wherein the 5' end is labeled with HEX fluorescence modification and the 3' end is labeled with BHQ1 quenching modification; The 796-797 specific repressor blocker sequence is CAGGA+G+GC+A+GC+C+G-C3Spacer, where "+" indicates that the base at that position has been modified with LNA, and all bases in the sequence are thiolated; the C3 Spacer modification is added to the 3' end of the sequence.
2. A kit for simultaneously detecting multiple cis-trans mutations in EGFR, characterized in that, The kit includes at least the primer-probe sequence combination as described in claim 1.
3. The reagent kit according to claim 2, characterized in that, The kit also includes a PCR reaction solution; the PCR reaction solution includes at least nuclease-free water, dNTPs, magnesium ions, buffer, and Taq enzyme.
4. The kit according to claim 2 or 3, characterized in that, The final concentration of each amplification primer is 100-400 nM, the final concentration of each probe is 50-200 nM, and the final concentration of the 796-797 specific repressor blocker is 500-2000 nM.
5. The use of the primer-probe sequence combination described in claim 1 in the preparation of reagents or kits for simultaneously detecting multiple cis-trans mutations in EGFR.
Citation Information
Patent Citations
Probe set used for detecting T790M and C797S cis-trans mutation types, kit, reaction system and system
CN109504777A
Detection method of EGFR T790M and C797S cis mutation
CN110004219A
Methods and probes for detecting cis-trans mutant configurations of EGFR-T790M and EGFR-C797S
CN111662986B
Primer group for detecting T790M and C797S mutations of EGFR (epidermal growth factor receptor) genes, application, kit and method
CN116200470A
Devices, systems and methods for analysis of nucleic acids
WO2025049623A1
